The instrumented timed up and go test: potential outcome measure for disease modifying therapies in Parkinson's disease
نویسندگان
چکیده
منابع مشابه
The timed up and go test for lumbar degenerative disc disease.
We report on the use and performance of an objective measure of functional impairment, the timed up and go (TUG) test, in clinical practice for patients with lumbar degenerative disc disease (DDD). We illustrate nine representative patients with lumbar DDD, who were selected from an ongoing prospective study, to report our clinical experience with the TUG test. In addition, a preliminary sample...
متن کاملInvestigation of the timed 'up & go' test in children.
The timed 'Up & Go' test (TUG) is a test of basic or functional mobility in adults which has rarely been used in children. Functional mobility was defined for this study as an individual's ability to manoeuvre his or her body capably and independently to accomplish everyday tasks. Reliability and validity of TUG scores were examined in 176 children without physical disabilities (94 males, 82 fe...
متن کاملEmerging oral disease-modifying therapies
Over the last two decades, patients have relied on the use of self-injectable disease modifying agents for the treatment of multiple sclerosis. The need for frequent injections has affected treatment up take and adherence. Fingolimod, the first oral disease modifying agent to be licensed in Europe and the United States, has been shown to be effective in reducing relapse rates in comparison to p...
متن کاملTimed "Up & Go" test in children and adolescents
OBJECTIVE To evaluate, by a literature review, the Timed "Up & Go" (TUG) test use and its main methodological aspects in children and adolescents. DATA SOURCES The searches were performed in the following databases: PubMed, CINAHL, Web of Science, SciELO and Cochrane Library, from April to July 2012. Studies published from 1990 to 2012 using the terms in Portuguese and English "Timed "Up & Go",...
متن کاملOral Disease-Modifying Therapies for Multiple Sclerosis
Classical multiple sclerosis (MS) treatments using first-line injectable drugs, although widely applied, remain a major concern in terms of therapeutic adherence and efficacy. New oral drugs recently approved for MS treatment represent significant advances in therapy. The oral route of administration clearly promotes patient satisfaction and increases therapeutic compliance. However, these drug...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Journal of Neurology, Neurosurgery & Psychiatry
سال: 2009
ISSN: 0022-3050
DOI: 10.1136/jnnp.2009.173740